Freedom Capital initiated coverage of Black Diamond Therapeutics (BDTX) with a Buy rating and $6 price target Lead program silevertinib has already delivered “encouraging” preliminary efficacy in Phase 2 development in non- small-cell lung cancer, says the analyst, who views Black Diamond as “well positioned to establish a foothold in the highly competitive precision oncology landscape.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- Black Diamond, TransMedics, Duolingo, AT&T, Coherus: Trending by Analysts
- Black Diamond Therapeutics initiated with a Buy at Guggenheim
- Black Diamond price target lowered to $10 from $12 at H.C. Wainwright
- Black Diamond Therapeutics Reports Strong Financial Turnaround
- Black Diamond Therapeutics reports Q2 EPS (19c), consensus (23c)